Focus on neuroscience and neuroprotection
Research focuses on processes involved in loss of neuronal function, with attention to acute and chronic nervous system diseases.
Peptide science for brain diseases
Peptide science for brain diseases.
PepTiDa is an innovative biotech startup and spin-off from the University of Milan, focused on highly targeted peptide-based approaches for severe brain diseases.
The platform combines neuroscience, peptide design and translational development to build therapeutic candidates focused on neuroprotection.
About
Development of peptide and peptidomimetic therapeutics.
PepTiDa develops peptide and peptidomimetic molecules designed to modulate biological pathways involved in neuronal damage, synaptic dysfunction and neurodegeneration.
Peptide science and innovation
The platform leverages peptide design, protein structure and target biology expertise to build selective candidates.
Translational and data-driven approach
The goal is to generate robust, interpretable preclinical evidence useful for regulatory development, partnerships and fundraising.
Science
Shared mechanisms across different brain diseases.
Many neurological diseases share convergent processes: neuronal stress, synaptic alteration, inflammation, mitochondrial dysfunction and progressive tissue damage. PepTiDa works on selected molecular targets to preserve neuronal structure and function.
Target biology
Selection of molecular pathways relevant to neuronal damage and biological response to treatment.
Biomarkers and readouts
Use of experimental markers and readouts to connect mechanism of action, target engagement and biological impact.
Preclinical validation
Progression from experimental evidence to stronger preclinical packages aligned with the regulatory path.
Approach
A multidisciplinary, AI-enabled model focused on execution.
PepTiDa aims to use scientific and industrial expertise, together with advanced digital tools, to make processes faster, more efficient and verifiable.
Discovery + Data + Execution
DesignPeptide science, protein structure and biological rationale.
DeriskingTargeted experiments to reduce scientific and regulatory uncertainty.
AI-enabledSupport for analysis, synthesis, documentation and decision-making processes.
PartnershipClear scientific packages for investors and industrial partners.
Asset protection
IP strategy supporting development, partnership and future licensing optionality.
Regulatory package
Data, toxicology, CMC and documentation organized toward an IND-enabling path.
Business development
Value creation tied to scientific and regulatory milestones, not only to market narrative.
Development
Preclinical-stage biotech platform.
The development path aims to strengthen SIMBA2 and the PepTiDa platform through preclinical validation, candidate characterization, formulation, regulatory planning and partnership readiness.
IND-enabling studies
Evidence package needed to prepare future regulatory dialogue.
CMC and manufacturability
Stability, formulation, quality and scalability of the therapeutic candidate.
Regulatory path
Roadmap aligned with EMA Scientific Advice and FDA Pre-IND discussions.
Roadmap
Clear value-creation milestones.
The investment request should be connected to measurable steps: completion of the preclinical package, regulatory readiness and preparation of a credible asset for partnership or licensing.
De-risking biology
Additional validation of the biological rationale, experimental models and translational readouts.
Preclinical package
Pharmacokinetics, preliminary toxicology, bioavailability, formulation and safety data.
CMC scale-up
Production, stability, quality and definition of requirements for GMP development.
Pre-IND / Scientific Advice
Preparation of the dossier for regulatory interactions and early clinical development.
Team
Scientific depth and biotech execution expertise.
The team combines over 35 years of neuroscience research with pharma, biotech, business development, fundraising, CMC, quality, regulatory development and industrial partnership expertise.
Tiziana Borsello
Chief Scientific Officer · Founder
Professor of Human Anatomy at the University of Milan, with over 35 years of research in neuronal death and neuroprotection.
Michela Pantaleoni
Chief Executive Officer
Executive profile with pharma and biotech experience in strategy, business development, investor readiness and execution.
Massimiliano Di Cicco
Chief Business Officer
International advisor with experience in biotech, pharma and MedTech across strategy, finance, BD and fundraising.
Senior expert network
PepTiDa is supported by a multidisciplinary advisory network covering the main capabilities needed to progress from preclinical evidence to a partnership-ready package.
Clinical developmentProtocol logic, translational endpoints and development sequencing.
RegulatoryEMA/FDA interaction planning and dossier readiness.
CMC & QualityManufacturing, formulation, stability and quality requirements.
BD & FundraisingInvestor readiness, partnering narrative and deal preparation.
News
Recognition and updates.
Institutional milestones and recognition that strengthen PepTiDa’s innovation and intellectual property value-creation path.
WIPO Global Awards
PepTiDa has been recognized among innovative companies using intellectual property as a driver of growth and impact.
Neuroscience funding
PepTiDa has received support through neuroscience research programs, strengthening the next phase of preclinical development.
Scientific collaborations, investors and industrial partnerships
PepTiDa is open to discussions with scientific, industrial and financial partners interested in developing new peptide-based therapies for brain diseases.